ZNTL

Elite Trades From Anywhere Elite Trades All Summer

$100 Off Your First Year Get Elite For Just $199.50

Jun 29, 11:02 AMAnalyst upgrade and azenosertib momentum propel 19.55% ZNTL surge

Peers: CCCC CHRS REPL ALEC CLLS IMRX ELDN LENZ GLSI RZLT

| Held by: VTI IWM VXF IWN FESM IWC DFAS VHT PRFZ AVSC

Index	-
Market Cap	359.85M
Enterprise Value	186.74M
Income	-124.13M
Sales	0.00M
Book/sh	2.57
Cash/sh	2.97
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	106
IPO	Apr 03, 2020

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	1.97
P/C	1.70
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	6.19
Current Ratio	6.19
Debt/Eq	0.21
LT Debt/Eq	0.19
Option/Short	Yes / Yes

EPS (ttm)	-1.74
EPS next Y	-1.68
EPS next Q	-0.48
EPS this Y	-1.45%
EPS next Y	13.53%
EPS next 5Y	7.13%
EPS past 3/5Y	24.78% 7.86%
Sales past 3/5Y	- -
EPS Y/Y TTM	44.78%
Sales Y/Y TTM	-100.00%
EPS Q/Q	25.31%
Sales Q/Q	-
Earnings	May 12 AMC
EPS/Sales Surpr.	-4.89% -

Insider Own	36.08%
Insider Trans	33.22%
Inst Own	52.63%
Inst Trans	-1.44%
ROA	-38.97%
ROE	-51.93%
ROIC	-57.12%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	31.87%
SMA50	27.91%
SMA200	95.27%
Trades

Shs Outstand	71.16M
Shs Float	45.50M
Short Float	10.95%
Short Ratio	2.27
Short Interest	4.98M
52W High	6.95 -27.27%
52W Low	1.13 347.35%
Volatility	11.03% 8.26%
ATR (14)	0.35
RSI (14)	72.48
Beta	1.92
Rel Volume	0.65
Avg Volume	2.19M
Volume	808,333

Perf Week	37.36%
Perf Month	26.37%
Perf Quarter	136.21%
Perf Half Y	271.69%
Perf YTD	274.44%
Perf Year	335.78%
Perf 3Y	-82.08%
Perf 5Y	-90.50%
Perf 10Y	-
Recom	2.11
Target Price	6.50
Prev Close	4.61
Price	5.05
Change	9.65%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-17-26	Resumed	Wells Fargo	Equal Weight	$5
Aug-12-24	Upgrade	Wedbush	Underperform → Neutral	$4
Jun-20-24	Downgrade	UBS	Buy → Neutral	$28 → $5
Jun-18-24	Downgrade	Wells Fargo	Overweight → Equal Weight
Jun-18-24	Downgrade	Wedbush	Neutral → Underperform	$15 → $4
Jun-18-24	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$38 → $8
Jun-18-24	Downgrade	Jefferies	Buy → Hold	$42 → $6
Nov-08-23	Downgrade	Wedbush	Outperform → Neutral	$38 → $12
Nov-07-23	Downgrade	Leerink Partners	Outperform → Market Perform	$15
Jul-12-22	Initiated	Cowen	Outperform
Apr-06-22	Initiated	Wells Fargo	Overweight	$67
Oct-07-21	Resumed	Jefferies	Buy	$120
Sep-30-21	Initiated	Stifel	Buy	$84
Sep-29-21	Initiated	Oppenheimer	Outperform	$90
May-21-21	Initiated	UBS	Buy	$91
Jan-20-21	Initiated	Wedbush	Outperform	$65
Sep-29-20	Initiated	Cantor Fitzgerald	Overweight	$44
Aug-27-20	Initiated	H.C. Wainwright	Buy	$43
Apr-28-20	Initiated	SVB Leerink	Outperform	$45
Apr-28-20	Initiated	Morgan Stanley	Overweight	$45

Show Previous Ratings

Jun-01-26 05:00PM	Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-27-26 04:05PM	Zentalis Strengthens Commercial Leadership with Appointments of Shannon Campbell to Board of Directors and Sarah Kelly as SVP of Commercial Strategy (GlobeNewswire)
May-21-26 05:39PM	Zentalis Pharmaceuticals to Present Phase 1b MUIR Trial Data Showing Encouraging Clinical Activity and Manageable Safety Profile of Azenosertib Plus Paclitaxel in Platinum-Resistant Ovarian Cancer at ASCO 2026 (GlobeNewswire) +11.59%
May-13-26 04:05PM	Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-12-26 04:05PM	Zentalis Pharmaceuticals Reports First Quarter 2026 Financial Results and Clinical Progress (GlobeNewswire)
08:00AM	Loading…
May-05-26 08:00AM	Zentalis Pharmaceuticals Announces First Patient Dosed in ASPENOVA Phase 3 Trial of Azenosertib in Patients with Cyclin E1-Positive Platinum-Resistant Ovarian Cancer (GlobeNewswire)
May-01-26 05:30PM	Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-21-26 10:27AM	Zentalis Pharmaceuticals Announces Abstract Acceptance at ASCO 2026 Featuring Azenosertib in Combination with Paclitaxel for Platinum-Resistant Ovarian Cancer (GlobeNewswire)
Apr-17-26 03:15PM	Zentalis Pharmaceuticals To Present Azenosertib Preclinical Data in Triple-Negative Breast Cancer and Real-World Analysis of Unmet Need in Cyclin E1-Positive Ovarian Cancer at AACR 2026 (GlobeNewswire) -7.57%
Apr-10-26 10:30AM	BC-Most Active Stocks (Associated Press) +49.55%
Apr-09-26 08:00AM	Zentalis Pharmaceuticals Announces 400mg QD 5:2 Azenosertib Monotherapy as the Pivotal Study Dose in Cyclin E1-Positive Platinum-Resistant Ovarian Cancer (GlobeNewswire) +60.14%
Apr-01-26 05:00PM	Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +9.83%
Mar-26-26 04:05PM	Zentalis Pharmaceuticals Reports Full Year 2025 Financial Results and Operational Updates (GlobeNewswire) -21.35%
Mar-17-26 04:30PM	Zentalis Pharmaceuticals to Present Two Posters at the American Association for Cancer Research (AACR) Annual Meeting 2026 (GlobeNewswire) -7.88%
Feb-18-26 08:00AM	Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
05:09AM	Loading…
Feb-16-26 05:09AM	Zentalis Pharmaceuticals Details Azenosertib Path to PROC Approval, DENALI Dose Pick Coming Soon (MarketBeat)
Feb-03-26 04:05PM	Zentalis Pharmaceuticals to Participate in Upcoming Investor Conference (GlobeNewswire) +12.35% -9.57%
Jan-13-26 08:45AM	Mitsui Sumitomo Continues to Build WR Berkley Stake (24/7 Wall St.)
Jan-12-26 10:35AM	Fast-Tracking the $537B Cancer Cure: How Accelerated Approvals Reshaping Oncology in 2026 (PR Newswire) -6.68%
Jan-06-26 08:00AM	Zentalis Pharmaceuticals Provides Corporate Update and Highlights Key Milestones and Expected Momentum in the Azenosertib Development Program for 2026 (GlobeNewswire) +29.93%
Nov-10-25 04:05PM	Zentalis Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operational Progress (GlobeNewswire) +6.06%
Nov-03-25 05:25PM	Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -8.33%
08:15AM	Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
Oct-13-25 04:05PM	Zentalis Pharmaceuticals Announces Four Azenosertib Posters Presentations at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (GlobeNewswire)
Oct-01-25 05:20PM	Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +7.79%
Sep-02-25 05:00PM	Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-28-25 04:15PM	Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-26-25 04:05PM	Zentalis Pharmaceuticals Appoints James B. Bucher, JD, as Chief Legal Officer and Corporate Secretary (GlobeNewswire)
Aug-06-25 04:05PM	Zentalis Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operational Progress (GlobeNewswire) +5.07%
Jul-01-25 05:00PM	Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
05:00PM	Loading…
Jun-02-25 05:00PM	Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.79% +6.25%
May-14-25 04:05PM	Zentalis Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Progress (GlobeNewswire) +5.88%
May-01-25 05:00PM	Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-28-25 08:00AM	Zentalis Pharmaceuticals Announces First Patient Dosed in DENALI Part 2 Clinical Trial of Azenosertib in Patients with Cyclin E1+ PROC (GlobeNewswire)
Apr-23-25 04:05PM	Zentalis Pharmaceuticals Announces Poster Presentation at 2025 ASCO Annual Meeting (GlobeNewswire)
Apr-01-25 05:30PM	Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -12.58%
Mar-26-25 04:05PM	Zentalis Pharmaceuticals Reports Full Year 2024 Financial Results and Operational Updates (GlobeNewswire) -5.88%
Mar-25-25 04:40PM	Zentalis Pharmaceuticals to Present Multiple Posters at the American Association for Cancer Research (AACR) Annual Meeting 2025 (GlobeNewswire) -5.56%
Mar-15-25 11:25AM	Zentalis Pharmaceuticals Presents Updated Clinical Data at the Society of Gynecologic Oncology 2025 Annual Meeting on Women's Cancer (GlobeNewswire)
Mar-03-25 05:00PM	Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -7.25%
08:00AM	Zentalis Pharmaceuticals Announces Multiple Data Presentations at Society of Gynecologic Oncology 2025 Annual Meeting on Women's Cancer (GlobeNewswire)
Feb-24-25 04:05PM	Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
Feb-21-25 12:21AM	Zentalis Pharmaceuticals (ZNTL): Among Cheapest Stocks Insiders Are Buying Recently (Insider Monkey) -6.07%
Feb-03-25 05:42PM	Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
09:35AM	Zentalis Pharmaceuticals (ZNTL) Loses -46.3% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Jan-30-25 10:20AM	Zentalis price target lowered to $10 from $20 at Oppenheimer (TipRanks) -12.17%
Jan-29-25 07:00AM	Zentalis Pharmaceuticals Shares Updated Clinical Data Demonstrating Meaningful Azenosertib Activity in Cyclin E1+, Platinum-Resistant Ovarian Cancer (GlobeNewswire) -21.25%
Jan-28-25 04:05PM	Zentalis Pharmaceuticals Announces Strategic Restructuring to Support Late-Stage Azenosertib Development (GlobeNewswire)
Jan-09-25 12:00PM	Zentalis Pharmaceuticals (ZNTL) Upgraded to Strong Buy: What Does It Mean for the Stock? (Zacks)
07:00AM	Zentalis Pharmaceuticals Announces Azenosertib Fast Track Designation and Virtual Corporate Event to Present Updated Data from Azenosertib Clinical Studies (GlobeNewswire)
Jan-02-25 04:53PM	Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +8.00%
Dec-12-24 07:00AM	Zentalis Pharmaceuticals Announces Key Management Appointments (GlobeNewswire) -10.57%
Dec-02-24 04:35PM	Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -8.20%
Nov-13-24 08:00AM	Zentalis Pharmaceuticals Announces Executive Leadership Changes Supporting Planned Registrational Clinical Studies of Azenosertib (GlobeNewswire) +5.66%
Nov-01-24 07:04PM	Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +21.61% +12.35%
Oct-18-24 03:05PM	State Street Corp's Strategic Reduction in Zentalis Pharmaceuticals Holdings (GuruFocus.com)
Oct-07-24 03:03PM	FMR LLC Adjusts Its Stake in Zentalis Pharmaceuticals Inc (GuruFocus.com) -7.72%
Sep-17-24 12:15PM	FDA lifts partial clinical hold on Zentalis Pharmas cancer WEE1 inhibitor (Pharmaceutical Technology) +11.41%
Sep-16-24 09:00AM	FDA Removes Partial Hold On Zentalis Pharmaceuticals' Azenosertib Studies In Patients With Gynecological Cancers (Benzinga) +13.58%
07:00AM	Zentalis Pharmaceuticals Announces FDA Has Lifted Partial Clinical Hold on Azenosertib Studies (GlobeNewswire)
Sep-09-24 07:00AM	Zentalis Pharmaceuticals to Present Preclinical Azenosertib Data at ESMO 2024 (GlobeNewswire)
Sep-03-24 04:40PM	Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -6.92%
Aug-26-24 11:58AM	Zentalis (ZNTL) Plunges More Than 70% in 3 Months: Here's Why (Zacks)
Aug-09-24 02:53PM	ZNTL Stock Earnings: Zentalis Pharma Misses EPS for Q2 2024 (InvestorPlace) -9.37%
07:00AM	Zentalis Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operational Progress (GlobeNewswire)
Aug-01-24 06:00PM	Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.00%
Jul-01-24 06:00PM	Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -14.80%
Jun-19-24 10:23AM	Zentalis (ZNTL) Tanks After FDA Puts 3 Cancer Studies on Hold (Zacks)
04:52AM	FDA places partial clinical hold on Zentalis trials of azenosertib for cancer (Clinical Trials Arena)
Jun-18-24 07:00AM	Zentalis Pharmaceuticals Provides Update on Azenosertib Clinical Development Program (GlobeNewswire) -50.66%
Jun-03-24 06:00PM	Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-01-24 02:43AM	Insider Selling at Zentalis Pharmaceuticals Inc (ZNTL): President, Interim CFO Cam Gallagher ... (GuruFocus.com)
May-30-24 07:00AM	Zentalis Pharmaceuticals to Present at the Jefferies Global Healthcare Conference (GlobeNewswire)
May-29-24 07:00AM	Zentalis Pharmaceuticals Announces Appointment of Accomplished Oncology Drug Developer Luke Walker, M.D., to Board of Directors (GlobeNewswire)
May-23-24 05:01PM	Zentalis Pharmaceuticals to Present Promising Results from Phase 1 Trial of Azenosertib and Gemcitabine in Relapsed or Refractory Osteosarcoma at 2024 American Society of Clinical Oncology Annual Meeting (GlobeNewswire) -5.84%
May-14-24 07:00AM	Zentalis Pharmaceuticals to Present at TD Cowen 5th Annual Oncology Innovation Summit (GlobeNewswire)
May-08-24 10:27AM	Stifel Adjusts Price Target on Zentalis Pharmaceuticals to $32 From $36, Maintains Buy Rating (MT Newswires)
May-07-24 09:04PM	Zentalis Pharmaceuticals Reports Q1 2024 Earnings: Surpasses Revenue Forecasts with Strategic ... (GuruFocus.com) +5.03%
01:54PM	ZNTL Stock Earnings: Zentalis Pharma Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
07:00AM	Zentalis Pharmaceuticals Reports First Quarter 2024 Financial Results and Operational Progress (GlobeNewswire)
May-01-24 05:30PM	Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-02-24 04:05PM	Zentalis Pharmaceuticals to Highlight Preclinical Data Demonstrating that WEE1 Inhibitor Azenosertib Exerts Synergistic Anti-tumor Activity with KRAS(G12C) Inhibitors at AACR Annual Meeting 2024 (GlobeNewswire) -10.54% +8.25%
Apr-01-24 05:30PM	Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-01-24 06:00PM	Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-28-24 09:55AM	Wall Street Analysts Think Zentalis Pharmaceuticals, Inc. (ZNTL) Could Surge 136.44%: Read This Before Placing a Bet (Zacks) +5.30%
07:00AM	Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences (GlobeNewswire)
Feb-27-24 07:01PM	Zentalis Pharmaceuticals Inc (ZNTL) Reports Full Year 2023 Financial Results and Provides ... (GuruFocus.com)
07:00AM	Zentalis Pharmaceuticals Reports Full Year 2023 Financial Results and Operational Updates (GlobeNewswire)
Feb-14-24 09:35AM	Down -19.06% in 4 Weeks, Here's Why You Should You Buy the Dip in Zentalis Pharmaceuticals, Inc. (ZNTL) (Zacks) +10.34%
Feb-13-24 07:00AM	Zentalis Pharmaceuticals to Participate in the Oppenheimer Healthcare Life Sciences Conference (GlobeNewswire) -5.83%
Feb-08-24 12:00PM	What Makes Zentalis Pharmaceuticals, Inc. (ZNTL) a New Buy Stock (Zacks)
Feb-05-24 11:26PM	Insider Sell: President Cam Gallagher Sells 11,552 Shares of Zentalis Pharmaceuticals Inc (ZNTL) (GuruFocus.com)
Feb-01-24 05:00PM	Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-25-24 07:00AM	Zentalis Pharmaceuticals Strengthens Management Team with Key Appointments (GlobeNewswire)
Jan-08-24 07:00AM	Immunome Exclusively Licenses Zentalis ROR1 Antibody-Drug Conjugate and Proprietary Technology Platform (Business Wire) +7.15%
Jan-02-24 04:49PM	Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +5.54%
Dec-01-23 05:39PM	Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-13-23 09:03PM	Director David Johnson's Strategic Purchase of Zentalis Pharmaceuticals Inc Shares (GuruFocus.com) +14.42%
Nov-09-23 07:00AM	Zentalis to Participate in Investor Call Focused on Ovarian Cancer with Gynecologic Oncology Key Opinion Leader Joyce F. Liu, M.D., MPH, Hosted by TD Cowen (GlobeNewswire)
Nov-06-23 07:13PM	Zentalis Pharmaceuticals Inc (ZNTL) Reports Q3 2023 Financial Results and Operational Updates (GuruFocus.com) -30.20% -18.27%

Zentalis Pharmaceuticals, Inc. is a clinical oncology innovator developing an oral, non-chemotherapy, biomarker-driven treatment approach for ovarian cancer and multiple tumor types. The therapeutics development and biomarker expertise is advancing monotherapy and combination studies of its investigational potential first-in-class WEE1 inhibitor, azenosertib. It is focused on translating WEE1 science into clinical practice, aiming to equip physicians with a targeted, orally available medicine that enhances treatment experience, choice, and outcomes. The company was founded by Kevin D. Bunker and Cam Gallagher on December 23, 2014 and is headquartered in San Diego, CA.

CEOMs. Julie M. Eastland M.B.A.

Chief Legal Officer & Corporate SecretaryMr. James B. Bucher J.D.

Ph.D.Dr. Ingmar Bruns M.D.

SVP of Finance & Principal Accounting OfficerMr. Vincent A. Vultaggio

Chief Technical OfficerMr. Robert J. DiVasto P.E.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Bruns Ingmar	Chief Medical Officer	Feb 06 '26	Sale	2.43	2,962	7,197	33,667	Feb 10 09:10 PM
Bruns Ingmar	Chief Medical Officer	Feb 09 '26	Sale	2.39	335	802	33,332	Feb 10 09:10 PM
Vultaggio Vincent	PAO and PFO	Feb 06 '26	Sale	2.43	29,951	72,772	156,779	Feb 10 09:10 PM
Vultaggio Vincent	PAO and PFO	Feb 10 '26	Sale	2.42	6,894	16,699	146,506	Feb 10 09:10 PM
Vultaggio Vincent	PAO and PFO	Feb 09 '26	Sale	2.39	3,379	8,086	153,400	Feb 10 09:10 PM
EASTLAND JULIA MARIE	CEO & President	Feb 06 '26	Sale	2.43	7,866	19,112	80,022	Feb 10 09:09 PM
EASTLAND JULIA MARIE	CEO & President	Feb 09 '26	Sale	2.39	889	2,127	79,133	Feb 10 09:09 PM
Vultaggio Vincent	PAO and PFO	Feb 02 '26	Sale	2.55	2,540	6,477	187,286	Feb 04 08:27 PM
Vultaggio Vincent	PAO and PFO	Feb 03 '26	Sale	2.52	556	1,398	186,730	Feb 04 08:27 PM
WALTERS GROUP	10% Owner	Dec 31 '25	Buy	1.20	6,459,973	7,751,968	13,509,973	Jan 08 04:57 PM
Matrix Capital Management Comp	10% Owner	Dec 15 '25	Sale	1.33	7,500,000	9,975,000	6,459,973	Dec 15 05:24 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

$100 Off Your First Year Get Elite For Just $199.50

Zentalis Pharmaceuticals Inc

Upgrade your Finviz experience